Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

Young Joo Lee, Chang Geol Lee, Byoung Chul Cho, Gwi Eon Kim, Hye Jin Choi, Eun Chang Choi, Joo Hyuk Sohn, Joo Hang Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer. Methods. In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m 2). Results. Thirty-two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression-free survival rates at 1 and 2 years were 69% and 66%, respectively. Conclusions. We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer.

Original languageEnglish
Pages (from-to)235-243
Number of pages9
JournalHead and Neck
Volume32
Issue number2
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Chemoradiotherapy
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Survival Rate
Radiation Dosage
Mucositis
Disease-Free Survival
Appointments and Schedules
Radiotherapy
Radiation
Survival

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Lee, Young Joo ; Lee, Chang Geol ; Cho, Byoung Chul ; Kim, Gwi Eon ; Choi, Hye Jin ; Choi, Eun Chang ; Sohn, Joo Hyuk ; Kim, Joo Hang. / Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. In: Head and Neck. 2010 ; Vol. 32, No. 2. pp. 235-243.
@article{f70de857c1974541b5e0e06dfef3af1b,
title = "Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer",
abstract = "Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer. Methods. In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m 2). Results. Thirty-two patients completed planned radiation. Thirteen (41{\%}) achieved complete response, and 16 (50{\%}) partial response. Twelve patients (38{\%}) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16{\%}) patients. The survival rates at 1 and 2 years were 81{\%} and 76{\%}, respectively. The progression-free survival rates at 1 and 2 years were 69{\%} and 66{\%}, respectively. Conclusions. We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer.",
author = "Lee, {Young Joo} and Lee, {Chang Geol} and Cho, {Byoung Chul} and Kim, {Gwi Eon} and Choi, {Hye Jin} and Choi, {Eun Chang} and Sohn, {Joo Hyuk} and Kim, {Joo Hang}",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/hed.21177",
language = "English",
volume = "32",
pages = "235--243",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. / Lee, Young Joo; Lee, Chang Geol; Cho, Byoung Chul; Kim, Gwi Eon; Choi, Hye Jin; Choi, Eun Chang; Sohn, Joo Hyuk; Kim, Joo Hang.

In: Head and Neck, Vol. 32, No. 2, 01.02.2010, p. 235-243.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

AU - Lee, Young Joo

AU - Lee, Chang Geol

AU - Cho, Byoung Chul

AU - Kim, Gwi Eon

AU - Choi, Hye Jin

AU - Choi, Eun Chang

AU - Sohn, Joo Hyuk

AU - Kim, Joo Hang

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer. Methods. In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m 2). Results. Thirty-two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression-free survival rates at 1 and 2 years were 69% and 66%, respectively. Conclusions. We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer.

AB - Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer. Methods. In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m 2). Results. Thirty-two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression-free survival rates at 1 and 2 years were 69% and 66%, respectively. Conclusions. We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=74749100448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749100448&partnerID=8YFLogxK

U2 - 10.1002/hed.21177

DO - 10.1002/hed.21177

M3 - Article

C2 - 19572288

AN - SCOPUS:74749100448

VL - 32

SP - 235

EP - 243

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 2

ER -